NCT00329901 - Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years | Biotech Hunter

Enrollment

1,072

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

December 31, 2007

Conditions

Meningococcal DiseaseMeningococcal Meningitis

Interventions

BIOLOGICAL

Meningococcal ACWY conjugate vaccine (MenACWY-CRM)

BIOLOGICAL

Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)

BIOLOGICAL

saline placebo

4.5 mg sodium chloride per 0.5 ml dose

Trial Locations (14)

Andria

Catania

Chieti

Ferrara

Genova

Lanciano

Massafra

Modena

Novara

Palermo

Pieve Di Soligo (TV)

Roma

Sassari

Taranto